HK1084015A1 - Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3-carboxylic acid derivatives - Google Patents
Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3-carboxylic acid derivatives Download PDFInfo
- Publication number
- HK1084015A1 HK1084015A1 HK06103919.6A HK06103919A HK1084015A1 HK 1084015 A1 HK1084015 A1 HK 1084015A1 HK 06103919 A HK06103919 A HK 06103919A HK 1084015 A1 HK1084015 A1 HK 1084015A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- composition
- weight
- composition according
- derivative
- intimate admixture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48251803P | 2003-06-26 | 2003-06-26 | |
US60/482,518 | 2003-06-26 | ||
PCT/US2004/020484 WO2005002548A1 (en) | 2003-06-26 | 2004-06-24 | Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
HK1084015A1 true HK1084015A1 (en) | 2006-07-21 |
HK1084015B HK1084015B (en) | 2009-07-24 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
EP1635792B1 (en) | 2009-03-04 |
ATE424192T1 (de) | 2009-03-15 |
CA2530788A1 (en) | 2005-01-13 |
MXPA06000226A (es) | 2006-03-21 |
ES2322854T3 (es) | 2009-06-30 |
EP1635792A1 (en) | 2006-03-22 |
US20050069586A1 (en) | 2005-03-31 |
PL1635792T3 (pl) | 2009-08-31 |
US20070212409A1 (en) | 2007-09-13 |
CA2530788C (en) | 2010-02-09 |
IL172602A0 (en) | 2006-04-10 |
DK1635792T3 (da) | 2009-06-15 |
PT1635792E (pt) | 2009-05-15 |
DE602004019777D1 (de) | 2009-04-16 |
WO2005002548A1 (en) | 2005-01-13 |
US20080058404A1 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080058404A1 (en) | Stable pharmaceutical compositions of 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivatives | |
EP2054040B1 (en) | Method for making solid dispersions of midostaurin | |
EP1334720B1 (en) | Nateglinide-containing preparations | |
CN104771364A (zh) | 固体组合物 | |
US11679105B1 (en) | Pharmaceutical compositions of cabozantinib | |
CA2732777A1 (en) | Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion | |
US20080008751A1 (en) | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | |
US20220387418A1 (en) | Pharmaceutical compositions of cabozantinib | |
HUT73657A (en) | Compositions in the form of solid solutions, containing coumarin derivatives | |
US20080015188A1 (en) | Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives | |
HK1084015B (en) | Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3-carboxylic acid derivatives | |
EP1864677B1 (en) | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | |
EP1889629B1 (en) | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | |
JP2813792B2 (ja) | マレイン酸イルソグラジン経口投与用製剤およびその製造法 | |
WO2015199115A1 (ja) | 経口投与用医薬組成物 | |
KR100484994B1 (ko) | 약학조성물 | |
CA3160393A1 (en) | A pharmaceutical oral dosage form of q203 | |
CA2659814A1 (en) | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | |
HK1116684A (en) | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | |
HK1117419A (en) | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20130624 |